Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
Abstract: The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.
Type:
Grant
Filed:
October 8, 2010
Date of Patent:
March 22, 2011
Assignee:
Intermune, Inc.
Inventors:
Williamson Ziegler Bradford, Javier Szwarcberg
Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
Abstract: Methods for treating viral infections using polyamine analogs, including mitoguazone (MGBG), are provided. In these methods, polyamine analogs destroy macrophages that act as viral reservoirs, facilitating the destruction of the viruses that dwell within the macrophages. Examples of viral infections that may be treated with the present methods include, but are not limited to, infections from human immunodeficiency viruses. These methods differ from previous methods of treatment using polyamine analogs, wherein the polyamine analogs were administered only as anti-tumor agents.
Abstract: A transdermal composition that contains an antipsychotic is provided for the treatment of neuropsychiatric disorders. Also, provided are methods for preparing a topical antipsychotic composition. Methods for treating neuropsychiatric disorders, including schizophrenia, are further disclosed. The transdermal composition includes a therapeutically effective amount of an antipsychotic in an amount sufficient to treat neuropsychiatric disorders in a pharmaceutically acceptable carrier.
Abstract: There are provided methods and compositions for improving the aesthetic appearance of akin, treating rosacea and/or telangiectasia, and treating the signs of dermatological aging. The method is directed to topically applying to an affected area an effective amount of mangostin, an analog thereof, or a combination thereof.
Abstract: Many chemical and pharmaceutical compositions are known to produce antinociceptive effects that are helpful in relieving pain and inflammation. Both opioids and local anesthetics serve an important function in providing peripheral pain relief. Topical administration of pain-relieving drugs to the periphery offers important advantages over systemic or local, non-topical administration. The present invention provides topical pharmaceutical compositions, formulated with at least one local anesthetic and at least one opioid analgesic in a topical excipient. The present invention also provides methods for relieving pain in a subject through topical administration of the pharmaceutical composition in an amount and a duration sufficient to synergistically potentiate an antinociceptive response. Synergistic potentiation of analgesia through topical administration of a local anesthetic/opioid pharmaceutical composition provides a new and improved approach to peripheral pain management.
Abstract: The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.
Type:
Grant
Filed:
January 8, 2010
Date of Patent:
October 19, 2010
Assignee:
Intermune, Inc.
Inventors:
Williamson Ziegler Bradford, Javier Szwarcberg
Abstract: A foundation in the form of a water-in-oil emulsion comprising a fatty phase, an aqueous phase, at least one surfactant chosen from C8-C22 alkyl dimethicone copolyols, at least one other surfactant chosen from dimethicone copolyols, and hydrophobic coated pigments, where the fatty phase comprises at least 30% by weight, relative to the total weight of the emulsion, of a volatile fatty phase comprising: at least 6% by weight, relative to the total weight of the emulsion, of at least one volatile hydrocarbon oil, and at least one volatile oil chosen from silicone volatile oils and fluorinated volatile oils; wherein the foundation is stable after storing at room temperature (25° C.) for at least 2 months and makes it possible to obtain a homogeneous make-up on the skin.
Abstract: A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more osteoarthritis treatment agent(s) is also disclosed.
Abstract: A method of treating or preventing Alzheimer's disease, Parkinson's Disease and/or schizophrenia, this method comprising administering to a patient in need of such treatment a compound of formula: in which R, R3 and R4 are as defined in the specification.
Type:
Grant
Filed:
November 12, 2004
Date of Patent:
June 22, 2010
Assignee:
Aventis Pharma S.A.
Inventors:
Daniel Achard, Herve Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
Abstract: The invention features a method for treating an immunoinflammatory administering a compound of formula (I), e.g., ibudilast or KC-764, alone or in combination with a corticosteroid, tetra-substituted pyrimidopyrimidine, or other compound. The invention also features pharmaceutical compositions including the combination above for the treatment or prevention of an immunoinflammatory disorder.
Type:
Grant
Filed:
November 19, 2004
Date of Patent:
May 4, 2010
Assignee:
CombinatoRx, Incorporated
Inventors:
Edward Roydon Jost-Price, Palaniyandi Manivasakam, Brendan Smith, Michael S. Slavonic, Benjamin A. Auspitz
Abstract: The present invention relates to novel inhibitors of prolyl endopeptidase of formula 1 W—KCONH—X—CON—Y—CO—Z??(1) wherein K, W, X, Y and Z are specified in the description. The compounds are useful for the treatment of diseases such as mild cognitive impairment (MCI), Alzheimer's disease, Down Syndrome, Parkinson disease and Chorea Huntington.
Type:
Grant
Filed:
November 30, 2005
Date of Patent:
February 23, 2010
Assignee:
Probiodrug AG
Inventors:
André Niestroj, Ulrich Heiser, Ingo Schulz, Jens-Ulrich Rahfeld, Joachim Baer, Hans-Ulrich Demuth
Abstract: Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.
Type:
Grant
Filed:
January 12, 2005
Date of Patent:
February 9, 2010
Assignee:
Avanir Pharmaceuticals, Inc.
Inventors:
Gerald Yakatan, James Berg, Laura E. Pope, Richard A. Smith
Abstract: The administration of nutritional supplements such as phosphatidylcholine; linoleic acid and alpha linolenic acid in an approximately 4:1 (v/v) ratio; and mineral supplements provides an effective method for the treatment of ALS. Subjects presenting with symptoms indicative of ALS can therefore be treated with these nutritional supplements to inhibit progression of ALS. Subjects at risk for developing ALS can also be treated with these nutritional supplements to delay the onset of ALS symptoms.
Abstract: In a solvent extraction process for preparing microspheres of a biodegradable polymer, the improvement comprising: preparing a homogenized antigen-sucrose matrix and adding a solvent to the sucrose-antigen matrix to form a solution; preparing a solution of a biodegradable polymer by adding a solvent to the polymer; adding the biodegradable polymer solution to the antigen-sucrose solution; adding an oil to the polymer-sucrose-antigen solution to form an emulsion having a controlled viscosity that corresponds to a predetermined average particle size of distributions of microspheres of biodegradable polymers; centrifuging the emulsion of controlled viscosity and removing the supernatant to obtain microspheres of a predetermined range of particle size distributions of from about 0.5 to about 7.0 micrometers.
Type:
Grant
Filed:
November 30, 1999
Date of Patent:
March 2, 2010
Assignee:
The United States of America as represented by the Secretary of the Army
Inventors:
Robert H. Reid, John E. VanHamont, William R. Brown, Edgar C. Boedeker, Curt Thies